Rani Devi
Active Director Director DIN 08347941
DIN 08347941 First appointment Jan 2019 Primary industry Trading
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2019
Shareholding value •••• Premium profile

About Rani Devi

Data last updated:

Rani Devi is a Director at Medcharm Pharmaceuticals Private Limited (since 2019). The company operates in Trading. Medcharm Pharmaceuticals Private Limited reported revenue of ₹17.6 Lakh (FY 2025).

DIN 08347941
Primary Designation Director
Industry Trading
First Appointment 31 Jan 2019
Oldest Company Age 7 yrs
Largest company Medcharm Pharmaceuticals Private Limited · ₹17.6 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director31 Jan 20192019₹17.6 Lakh (FY 2025)Active

Board colleagues of Rani Devi

NameDINCompanyDesignation
Mukesh Raj Singh08347940Medcharm Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Medcharm Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rani Devi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rani Devi

Rani Devi currently holds 1 directorship: Medcharm Pharmaceuticals Private Limited (Director, since 31 Jan 2019, revenue ₹17.6 Lakh (FY 2025)).

Rani Devi was first appointed on 31 Jan 2019 as Director at Medcharm Pharmaceuticals Private Limited.

The current boards of Rani Devi's companies include Mukesh Raj Singh (Medcharm Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available